Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMB-07 in Advanced Solid Tumors and Lymphoma
NCT05607498Phase 1Recruiting
- Sponsor
- EpimAb Biotherapeutics
- Start
- Mar 2023
- Primary completion
- Oct 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of EMB-07 in solid tumor, lymphoma, triple-negative breast cancer (TNBC) and 12 more (2 cohorts), sponsored by EpimAb Biotherapeutics. Primary endpoints: Incidence and severity of adverse events, Incidence of serious adverse events and 3 more. Started Mar 2023; status: recruiting.
02
Drugs
EMB-07
03
Conditions
solid tumorlymphomatriple-negative breast cancer (TNBC)lung adenocarcinomaovarian cancer
Beyond the preview
Go deeper on NCT05607498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607498.